USPTO Patent Applications - Pharma (A61K)

Akkermansia Muciniphila Akk11 Strain Regulates Blood Glucose and Blood Lipid

USPTO published patent application US20260108566A1 for Akkermansia muciniphila Akk11 (deposit number CCTCC NO: M 2024119). The application claims the strain uses mucin as the sole carbon and nitrogen source to regulate glucose and energy metabolism, protecting intestinal epithelial cells and mucus layer while regulating blood glucose and blood lipid levels, with potential applications for obesity and metabolic disorder treatment. The patent application names six inventors and was filed on 2024-07-08.

Nihon Pharmaceutical Muscle Proteoglycan Patent, Apr 23

NIHON PHARMACEUTICAL CO., LTD. has filed patent application US20260108563A1 titled 'COMPOSITION FOR IMPROVING OR MAINTAINING MUSCLE QUANTITY OR MUSCLE STRENGTH', published April 23, 2026. The invention covers a novel method for producing proteoglycan by immersing a biological sample in an aqueous surfactant solution, and its use in improving muscle quantity or strength and preventing obesity or reducing body fat percentage. The application was originally filed on August 3, 2023 under application number 19100791, with Tatsuya Wada listed as inventor.

Stem Cell Microglia Transplant Leukodystrophy Treatment

USPTO published patent application US20260108560A1 titled 'Transplanting Stem Cell-Derived Microglia to Treat Leukodystrophies' on April 23, 2026. The application covers myeloid cells, microglial progenitor cells, and microglia-like cells in which mutant genes have been repaired or replaced, and methods of using such cells to treat disease. Seven inventors are named including Mathew Blurton-Jones, Hayk Davtyan, Jean Paul Chadarevian, Robert Spitale, Sunil Gandhi, Jonathan Hasselmann, and Whitney England.

Composition for Neural Precursor Cell Therapy, Singapore

The United States Patent and Trademark Office published patent application US20260108561A1, filed by National University of Singapore (assignee) on October 3, 2023. The application covers a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into neurological injury or disease sites, comprising a gel forming molecule and a CCR5 antagonist. Also disclosed are methods of treating neurological injuries using NPC transplantation with this composition and a kit containing the composition, artificial cerebral spinal fluid, CaCl2, and thrombin.

Memorial Sloan-Kettering C. difficile Infection Patent

Memorial Sloan-Kettering Cancer Center's patent application US20260108564A1 was published April 23, 2026, disclosing methods and compositions for reducing the risk and severity of C. difficile infection. Application No. 19303846 was filed August 19, 2025, naming Eric Pamer, Charlie Buffie, and Peter McKenney as inventors. The invention is based on the discovery that a restricted fraction of gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection through the biosynthesis of secondary bile acids.

Bacillus Amyloliquefaciens Feed Additive for Aquaculture

USPTO published Application US20260108567A1 on April 23, 2026, covering a feed additive combining Bacillus amyloliquefaciens and postbiotics of Lactobacillus paracasei for use in aquaculture. The application, filed October 22, 2024, names YU-FEN LIU, WEI-CHIH HUANG, and YU-HUNG LIN as inventors. CPC classifications include A61K 35/742, A23K 10/18, and A23K 10/30. This publication does not impose compliance obligations on other parties; it is an informational record of a pending intellectual property claim.

Method for Preparing Targeted Dermal Papilla Cell-Derived Exosomes, Exosome Product, Liquid Hair Growth Formulation

US Patent Application US20260108562A1, filed October 7, 2025 and published April 23, 2026, discloses a method for preparing targeted exosomes from dermal papilla cells (DPCs) isolated using cell surface marker CD133 from hair follicles of healthy donors in a xeno-free and serum-free environment, with exosomes possessing surface markers CD9, CD63, and CD81 isolated via tangential flow filtration or size exclusion chromatography. The application also covers a liquid hair growth formulation incorporating the resulting lyophilized exosome product. This represents an early-stage intellectual property filing in the hair growth and exosome therapeutics space with no compliance obligations currently in effect.

US Patent Application A1 - Fiber Probiotic Combination for Regulating Cholesterol

USPTO published patent application US20260108569A1 (A1) on April 23, 2026, for a composition combining at least one fiber and at least one probiotic for oral administration to regulate gut bacteria association with cholesterol levels. The five inventors are Marc Garcia-Gar cera, Sami Damak, Bernard Berger, Fabio Mainardi, and Clara Lucia Garcia-Rodenas. The application was filed on October 30, 2023, under application number 19123666, with CPC classifications spanning A61K compounds including prebiotics and dietary fibers.

Ascension Medical Biotechnology Primed EVs for Bone, Dental Defects

Ascension Medical Biotechnology Co., Ltd. has filed US Patent Application US20260108559A1 with the USPTO, published on 23 April 2026 (filed 23 October 2025). The application covers primed extracellular vesicle compositions comprising upregulated miRNA and a biologically or pharmaceutically acceptable carrier, alongside methods of producing the compositions via stem cell cultivation with Polygonum multiflorum Thunb extract, baicalin, and bone morphogenetic protein 6. Claims encompass therapeutic use for preventing, treating, or ameliorating bone defects and dental defects in subjects in need thereof.

Iron Octasaccharide Complexes for Companion Animal Therapy

USPTO published patent application US20260108551A1 on April 23, 2026, covering iron octasaccharide complexes for subcutaneous administration in methods of treating iron deficiency, particularly iron deficiency anaemia, in companion animals. The application, originally filed August 3, 2022, names three inventors: Hans B. Andreasen, Tobias S. Christensen, and Simon M. Guldberg. The invention extends to pharmaceutical compositions comprising an iron octasaccharide complex and a pharmaceutically acceptable carrier for veterinary therapeutic use.

Dendrobium Polysaccharides and Vancomycin Bacteria for Intestinal Treatment

The USPTO published patent application US20260108552A1 on April 23, 2026, filed by the Hong Kong Authentication Centre of Valuable Chinese Medicines (Application No. 19306545, filed August 21, 2025) covering therapeutic uses of Dendrobium polysaccharides and vancomycin-sensitive bacteria for intestinal disorders including inflammatory bowel disease.

Nicotinamide Mononucleotide Derivatives for Treatment and Prevention of Sickle Cell Disease

The USPTO has published patent application US20260108550A1, filed June 13, 2025 (Application No. 19237807), covering nicotinamide mononucleotide (NMN) derivatives of Formula (I) for use in treating and/or preventing red blood cell disorders, specifically sickle cell disease. Inventors include Guillaume Bermond, Laurent Garçon, Matthias Canault, and Cecile Cros. The application is classified under CPC codes A61K 31/706, A61K 31/198, and A61P 7/06.

Abelzeta Files Bispecific CAR Patent for CD20 and BCMA

Abelzeta Inc. filed US Patent Application US20260108556A1 covering bispecific chimeric antigen receptors (CARs) that simultaneously target CD20 and BCMA antigens. The CAR constructs comprise an anti-CD20 scFv, an anti-BCMA scFv, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The filing was submitted on October 13, 2025, under Application No. 19356548, and names six inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Xin Yao, Xiaobing Luo, and Yutian Wei. The claimed compositions are directed toward treating autoimmune disorders and cancer.

Magnesium Salts Composition for Topical Skin Inflammation

The USPTO published patent application US20260108553A1 on April 23, 2026, filed by Instituto de Dermatología Ignacio Umbert, S.L. The application covers a composition comprising at least one magnesium salt, at least one non-magnesium salt, at least one antioxidant, and at least one plant extract, intended for treating skin inflammation pathologies. CPC classifications span A61K categories including magnesium compounds, antioxidants, and botanical extracts.

Methods for Reprogramming and Gene Editing Cells

The USPTO published patent application US20260108554A1 on April 23, 2026, filed on May 1, 2023 under application number 18861162. The application names seven inventors — Matthew ANGEL, Christopher ROHDE, Ian HAY, Ismet Caglar TANRIKULU, Tae Yun KIM, Abigail BLATCHFORD, and Mackenzie PARMENTER — and covers improved methods for reprogramming and gene editing cells, including manufacturing lymphoid and myeloid lineage cell populations. CPC classifications span cell therapy (A61K), proteins (C07K), and gene editing technologies (C12N).

US20260108555A1 - Cell Memory Regulation Without Genetic Modification

Victor TETS and Georgy TETS filed US Patent Application 19335515 for products and methods regulating cell behavior, cell memory, and erasure of cell memory across medicine, biology, veterinary, pharmacology, diagnostics, agriculture, ecology, and biotechnology. The patent was published April 23, 2026 (US20260108555A1) with CPC classifications in A61K 35/17, A61K 35/15, A61K 35/19, A61P 35/00, and C12N 9/22. The application claims a novel method to control cell and organism properties without using mutagens, gene introduction, gene tools, or environmental changes — distinguishing it from prior art in cellular regulation and biomanufacturing.

Aminergic Phytocannabinoids Derivatives as Multi-Target Agents for Neurological Disorders

The University of South Carolina has filed patent application US20260108541A1 with the USPTO for aminergic phytocannabinoid derivatives as multi-target agents for treating neurological disorders in mammals including humans. The application covers CBD derivatives functionalized at position 7 and THC derivatives functionalized at position 11. Inventors are Juan Francisco Leon Oyola and Zachary I. Stryker.

Macrolide Compound Patent Application, Institute of Feed Research, Chinese Academy of Agricultural Science

The USPTO has published patent application US20260108549A1 for a macrolide compound, filed by the Institute of Feed Research under the Chinese Academy of Agricultural Sciences, with inventors Xiubo LI, Fei XU, Yiming LIU, and Xiaojie CHEN. The application, filed May 31, 2024, covers pharmaceutical and veterinary compositions containing the macrolide compound for treating pathogen infections, especially in animals. Patent applications are published to establish priority and allow public review of the invention.

Novel Liquid Oral CBD Formulations, Published Apr 23

The USPTO published patent application US20260108540A1 on April 23, 2026, covering stable liquid oral pharmaceutical formulations of synthetic Cannabidiol (CBD). The application, filed June 24, 2023 (Application No. 19120456), names inventors Chandrashekhar KOCHERLAKOTA and Srinivas ARUTLA. The formulations comprise synthetic CBD combined with pharmaceutical excipients including solvents, oils, organoleptic modifiers, buffers, and surfactants.

Tryptamine Compositions for Enhancing Neurite Outgrowth

US Patent Application US20260108544A1, filed February 7, 2025 and published April 23, 2026, covers neurotrophic and nootropic compositions comprising tryptamines from psilocybin-containing mushrooms, optionally combined with phenethylamines, amphetamines, erinacines, hericenones, and cannabinoids. The application names Paul Edward Stamets as inventor and lists multiple CPC classifications spanning pharmaceutical chemistry and botanical extracts. This publication makes the application publicly available for review and potential opposition prior to grant.

L-fucose Treats Infectious Diseases and Cancers - US20260108547A1

The USPTO has published patent application US20260108547A1, filed on October 4, 2023, disclosing methods for treating infectious diseases and cancers by administering L-fucose to a subject. The application names Eric LE-LAU as inventor and claims therapeutic uses of the monosaccharide L-fucose in medical treatments. This patent publication establishes prior art and may affect freedom-to-operate analyses for competing therapeutics developers.

Self-Emulsifying Cannabinoid Tablet Formulations by Fertin Pharma

Fertin Pharma A/S has filed USPTO Application US20260108543A1 for an orally dissolvable or chewable tableted powder formulation incorporating self-emulsifying systems loaded with at least 10% cannabinoids by weight. The formulation includes 20-80% water-soluble agents by weight, one or more flavors, and surfactants containing polyethylene glycol moieties. The application covers both liquid self-emulsifying systems (with surfactants, lipids, and isolated or synthetic cannabinoids) and solid self-emulsifying systems (with surfactants, waxes, and isolated or synthetic cannabinoids). Filing date was December 22, 2025.

Paeoniflorin-Isoliquiritigenin Composition Treats Pulmonary Fibrosis

The USPTO has published patent application US20260108548A1, assigned to Henan University of Chinese Medicine, covering a therapeutic composition of paeoniflorin and isoliquiritigenin for treating diffuse interstitial pulmonary fibrosis. The application was filed on October 8, 2023 (Application No. 19129203) and names nine inventors including Jiansheng Li and Peng Zhao. The composition is claimed to provide anti-inflammatory, antioxidant, and collagen deposition inhibition effects. Patent applications are informational publications — no examination or grant decision has been made.

Syqe Medical Ltd. THC Inhaler, 0.75mg Max

Syqe Medical Ltd. filed patent application US20260108542A1 on December 19, 2025 (application no. 19426146), published April 23, 2026, covering a THC inhaler system with a scheduled regimen that caps delivery at 0.75 mg THC or less over a minimum 2-hour period. The system includes a memory storing the regimen, a decision module that determines whether delivery should occur, and a controller in the inhaler device executing delivery based on those decisions. The named inventors include Perry Davidson, Seth Kindler, Shlomo Almog, Binyamin Schwartz, Aaron Schorr, and Daniella Atzmony.

GIP Receptor Agonist Compounds for Diabetes, Obesity

The USPTO published patent application US20260108546A1 on April 23, 2026, covering GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonist compounds and their pharmaceutical compositions for the treatment of type II diabetes mellitus and obesity. The application, filed June 17, 2025, names 18 inventors and includes detailed CPC classifications spanning pharmaceutical chemistry, heterocyclic compounds, and organophosphorus compounds. This publication establishes a priority date and makes the claims publicly available for prior art review by competitors and researchers in the metabolic therapeutics space.

Meibomian Gland Dysfunction Treatment Using Keratolytic Agents

USPTO inventors Yair Alster, Omer Rafaeli, Kirsten Angela Macfarlane, Cary Reich, Shimon Amselem, and Doron Friedman filed Application US20260108533A1 on August 29, 2025 (Application No. 19315391), published April 23, 2026. The application discloses topical compositions comprising keratolytic agents such as salicylic acid or selenium disulfide for treating meibomian gland dysfunction via administration to the eyelid margin. Pharmaceutical companies developing ophthalmic or dermatologic therapeutics should review the disclosed claims for freedom-to-operate implications and competitive landscape assessment.

Cannabis Nanoplatform Treats Menopause Symptoms, Published 23rd Apr

USPTO published patent application US20260108538A1 (filed October 21, 2024) for a cannabinoid-based nanoplatform composition targeting menopause symptoms. The composition combines phytocannabinoids (CBD, CBG, CBN) with isoflavones and polyphenols in a nanoplatform designed for enhanced bioavailability and controlled release. The disclosed kit includes oral capsules and intravaginal ovules formulated to address vasomotor symptoms, genitourinary syndrome of menopause, bone loss, mood disturbances, sleep disorders, and cardiovascular disease risks.

Methods for Treatment of Psoriatic Arthritis - Patent Application US20260108530A1

Three inventors — Pille Harrison, Luc Meuleners, and Chantal Thérèse Tasset — filed Application US20260108530A1 on 2025-05-13, published April 23, 2026, covering a compound according to Formula I, or a pharmaceutically acceptable salt, solvate, or salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis. The application is classified under CPC codes A61K 31/541 and A61P 19/02.

Compound A Methods for RAS Protein-Related Disease Treatment

USPTO published patent application US20260108528A1 on April 23, 2026, covering methods of treating RAS protein-related diseases using Compound A or a pharmaceutically acceptable salt thereof, including combination therapies with additional therapeutic agents. The application (No. 19363949) was filed October 21, 2025, naming nine inventors: Jingjing Jiang, Lingyan Jiang, Benjamin Maldonato, Mallika Singh, Sophia Sohoni, Zhengping Wang, Zhican Wang, Caroline E. Weller, and Muhammad Ali. CPC classifications include A61P 35/00 (antineoplastic) and various protein/antibody classifications, indicating cancer treatment applications.

Fused Amino Pyrimidine Compounds Treat Tinnitus, Hearing Loss, Meniere's

USPTO published Patent Application US20260108529A1 on April 23, 2026, filed by inventor Zhong Zhong on October 23, 2025 (Application No. 19366802), covering fused amino pyrimidine compounds for treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, and Meniere's disease. The application discloses therapeutic compositions containing compounds according to Formula (I) or their pharmaceutically acceptable salts, classified under CPC codes A61K 31/5377, A61K 31/519, A61K 31/5517, A61K 45/06, and A61P 27/16.

Transnasal Testosterone Gel for Hypogonadism in Males with Allergic Rhinitis

USPTO published patent application US20260108531A1 by inventor Natalia Tkachenko on April 23, 2026, covering methods of treating hypogonadism in males via intranasal testosterone bio-adhesive gel formulations. The application discloses 4.0% and 4.5% testosterone gel compositions that remain effective when allergic rhinitis occurs or when topical nasal vasoconstrictors or decongestants are used during treatment. Filing date was March 20, 2025; application number 19085870.

Cannabinoid Nanoplatform Treats Knee Osteoarthritis

USPTO published patent application US20260108539A1, filed October 21, 2024 by Cannabis Bioscience International Holdings Inc, covering a cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis via intra-articular injection. The composition combines phytocannabinoids CBG and CBC with hyaluronic acid, type II collagen, and calcium gluconate, targeting joint pain, stiffness, reduced mobility, inflammation, and cartilage degeneration in osteoarthritis patients. The nanoemulsification-based production process creates particles smaller than 200 nm with pre-sterilization via membrane filtration.

Pharmaceutical Composition for Preventing Heart Disease and Pulmonary Hypertension in Animals

CARESIDE CO., LTD. has published patent application US20260108532A1, filed September 6, 2023, covering a pharmaceutical composition for preventing and treating heart disease and pulmonary hypertension in animals. The composition includes the active pharmaceutical ingredients pimobendan, enalapril, torsemide, and spironolactone. The application was published on April 23, 2026, under CPC classifications A61K and A61P relating to pharmaceutical preparations for cardiovascular conditions.

Bradykinin Receptor Antagonist Compounds for Pain Relief

The USPTO published patent application US20260108535A1 on April 23, 2026, covering bradykinin receptor antagonist compounds for therapeutic use. The application (No. 19423236, filed December 17, 2025) specifies pharmaceutical compositions for treatment of urinary bladder pain and symptomatic relief of pain, burning, urgency, and frequency arising from lower urinary tract mucosa irritation caused by infection, trauma, surgery, endoscopic procedures, or catheter passage. The named inventors include Pathik Subhashchandra Brahmkshatriya, Vishal Bharatbhai Unadkat, Vishalgiri Gunvantgiri Goswami, Heta Nishil Pandya, and Sandip Pareshbhai Mehta.

Liposomal BCL Inhibitors for Hyperproliferative Disorders

USPTO published patent application US20260108534A1 on April 23, 2026, filed September 30, 2025 under Application No. 19345495. The application covers liposomes containing B-cell lymphoma (Bcl) protein inhibitors, pharmaceutical compositions thereof, and methods of using such formulations for treating hyperproliferative disorders. Inventors: Paul Tardi, Leon Wan, Shyam Madhusudan Garg, Jun Gao, and Philippe Legros.

Shingles Treatment Cannabinoid Nanoplatform CBD CBG

Cannabis Bioscience International Holdings Inc published USPTO patent application US20260108537A1 on April 23, 2026 (filed October 18, 2024, Application No. 18920359), disclosing a cannabinoid-based nanoplatform for treating shingles using CBD and CBG in oral capsule and topical cream formulations with particles smaller than 200 nm. The invention targets acute shingles symptoms and postherpetic neuralgia with systemic anti-inflammatory, antiviral, and neuroprotective effects alongside localized pain and itch relief. This is a patent publication event creating no compliance obligations.

Cannabis Bioscience Nanoparticle Breast Cancer Treatment

Cannabis Bioscience International Holdings Inc has filed patent application US20260108536A1 for a cannabinoid-based nanoplatform composition targeting breast cancer treatment. The composition incorporates phytocannabinoids (THC, CBD, CBG, CBC) into nanoparticles smaller than 200 nm using nano-emulsification techniques for enhanced bioavailability and controlled release. The treatment targets ER+, PR+, HER2-positive, and triple-negative breast cancers at stages I and II by inhibiting VEGF pathways and inducing apoptosis.

Silver Nanoparticle Treatment for Carious Lesions, 3-5 Weeks

The USPTO published patent application US20260096959A1 filed by R.M CREIGHTON DENTAL PTY LTD for a method of treating carious lesions using silver nanoparticles. The treatment involves applying a first dental solution containing a silver salt followed by a second dental solution containing a reducing agent within less than 10 minutes. The lesion consolidates over 3-5 weeks to form a matte black crust containing nanoparticles. Invented by Graham G. Craig.

Anhydrous Powder Hair Lightening Suspension

USPTO published patent application US20260096960A1 by inventor David Erlingheuser for an anhydrous powder hair lightening suspension composition on April 9, 2026. The composition comprises 5-60% non-volatile oil, 3-30% petrolatum, 0.05-5% fumed silica, 1-70% persulfate salt, and 0% microplastics. This publication establishes a priority date and provides public notice of the pending patent claims.

Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue

USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.

Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1

USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.

Cancer Therapy Delivery System with Tumbling Container for Suspension Generation

USPTO published patent application US20260096951A1 for a cancer therapy delivery system featuring a tumbler vial for generating therapeutic microsphere suspensions. The system includes a rotation mechanism, fluid inlet and outlet lines configured to twist during rotation, and a cap occluding the vial end. The application was filed on October 9, 2025.

Polymeric Delivery System Patent for Biologics

USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.

Biodegradable Microcapsules and Method for Their Preparation

USPTO published patent application US20260096991A1 for biodegradable microcapsules and methods for their preparation. The application relates to microcapsule compositions for drug delivery, classified under A61K. Filing date was September 7, 2023, with nine listed inventors.

Teardrop Effervescent Tablet, Rapid Dissolution, Oral Drug Delivery

USPTO published patent application US20260096993A1 for a teardrop-shaped effervescent tablet designed for rapid dissolution oral drug delivery. The application (No. 18909065) was filed on October 8, 2024 and published April 9, 2026. Inventors Philip Mackenzie and Dan Aziz disclose a tablet with asymmetric geometry and cupped surfaces engineered to accelerate dissolution rates and improve bioavailability of active ingredients.

Solid Dispersions Having Stabilized Emulsion Particles Patent Application

USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).

Liquid Formulation of Belumosudil - Kadmon Corporation

USPTO published patent application US20260097036A1 by Kadmon Corporation on April 9, 2026, covering liquid formulations comprising belumosudil, an immunosuppressive agent used in the treatment of subjects. The application was filed on September 20, 2023, under Application No. 19113101, with inventors Olivier Schueller, Galit Regev, Mark Beville, and Nazim Kanji. The published application includes claims directed to liquid pharmaceutical compositions of belumosudil and processes for preparing such formulations.

Kyoto University Pancreatic Endoderm Cell Production Method

USPTO published patent application US20260097083A1 by Kyoto University for a method of producing pancreatic endoderm cells involving culturing the cells in a medium containing a ROCK inhibitor combined with KGF and/or EGF. The application names inventors Kenji Osafune, Yu Hatano, and Azuma Kimura, with CPC classifications spanning A61K 35/39 and C12N 5/0676.

Floating IPN Drug Delivery System for Extended Release

USPTO published patent application US20260096986A1 covering pharmaceutical compositions with a floating interpenetrating polymer network (IPN) system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent. Upon oral ingestion, the compositions form a floating IPN in situ that provides extended release of the entrapped drug for at least approximately 3 hours. The application was filed on December 12, 2025, under application number 19418060.

BlueRock Therapeutics LP Graft-Related Arrhythmia Treatment Patent Application

The USPTO published patent application US20260097012A1 by BlueRock Therapeutics LP on April 9, 2026, disclosing methods of treating or preventing graft-related arrhythmia in cardiac graft patients by administering combinations of anti-arrhythmic agents including amiodarone, metoprolol, ivabradine, and mexiletine. The application was originally filed on September 27, 2023. This published application makes the invention publicly available for examination and potential licensing or competitive intelligence purposes.